Keith A Betts

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 7

Top Topics

Clostridium Difficile

Advanced Non Small Cell Lung Cancer

Top Venues

Future oncology (London, England)

Cancer immunology, immunotherapy : CII

Crohn's & colitis 360

This page only lists publications with an associated author ORCID identifier.

Publications

Keith A Betts, Sophie Gao, Saurabh Ray, Adam J Schoenfeld
Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancer. Future oncology (London, England) 20 (13) (2024)
Scott David Lee, Keith A Betts, Ella Xiaoyan Du, Xiaoyu Nie, Komal Gupte-Singh, Timothy Ritter
Real-World Patterns and Economic Burden Associated With Treatment Failure With Advanced Therapies in Patients With Moderate-to-Severe Ulcerative Colitis. Crohn's & colitis 360 6 (2) (2024)
Keith A Betts, Sophie Gao, Saurabh Ray, Adam J Schoenfeld
Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancer. Future oncology (London, England) 20 (13) (2024)
Scott David Lee, Keith A Betts, Ella Xiaoyan Du, Xiaoyu Nie, Komal Gupte-Singh, Timothy Ritter
Real-World Patterns and Economic Burden Associated With Treatment Failure With Advanced Therapies in Patients With Moderate-to-Severe Ulcerative Colitis. Crohn's & colitis 360 6 (2) (2024)
Keith A Betts, Sophie Gao, Saurabh Ray, Adam J Schoenfeld
Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancer. Future oncology (London, England) (2024)
Jeffrey S Weber, Tayla Poretta, Brian D Stwalley, Leon A Sakkal, Ella X Du, Travis Wang, Yan Chen, Yan Wang, Keith A Betts, Alexander N Shoushtari
Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival. Cancer immunology, immunotherapy : CII (2022)
Jeffrey S Weber, Tayla Poretta, Brian D Stwalley, Leon A Sakkal, Ella X Du, Travis Wang, Yan Chen, Yan Wang, Keith A Betts, Alexander N Shoushtari
Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival. Cancer immunology, immunotherapy : CII (2022)